Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting -November 07, 2023 at 04:20 pm EST

ALPHARETTA, Ga., Nov. 07, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,...

Related Keywords

United States ,American ,George Lasezkay ,Jenny Kobin ,Triamcinolone Acetonide Suprachoroidal ,Remy Bernarda ,Belzupacap Sarotalocan ,Markr Barakat ,Rahuln Khurana ,American Academy Of Ophthalmology ,Suprachoroidal Administration ,Late Breaker Development ,Globenewswire Inc ,Nasdaq ,Clearside Biomedical Inc ,Linkedin ,Exchange Commission ,Annual Meeting ,Chief Executive ,Aura Biosciences ,Special Protocol Assessment ,Axitinib Injectable Suspension ,Extension Study ,Suprachoroidal Delivery ,Gene Therapy ,Diabetic Retinopathy Severity Scale ,Targeted Investigational Therapy ,Choroidal Melanoma ,Uveitic Macular Edema ,Suprachoroidal Space ,Injection Platform ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Periodic Reports ,Media Contacts ,Markets ,